Feasibility Study of Adjuvant Chemotherapy of S-1 and Carboplatin for Completely Resected Non-Small Cell Lung Cancer

被引：5

作者：

Komazaki, Yoshitoshi ^{[1
]}

Sakashita, Hiroyuki ^{[1
]}

Furuiye, Masashi ^{[1
]}

Fujie, Toshihide ^{[1
]}

Tamaoka, Meiyo ^{[1
]}

Sumi, Yuki ^{[1
]}

Miyazaki, Yasunari ^{[1
]}

Kojima, Katsuo ^{[2
,3
]}

Jin, Yasuto ^{[4
]}

Inase, Naohiko ^{[1
]}

机构：

[1] Tokyo Med & Dent Univ, Dept Integrated Pulmonol, Tokyo 1138519, Japan

[2] Tokyo Med & Dent Univ, Dept Cardiothorac Surg, Tokyo 1138519, Japan

[3] Musashino Red Cross Hosp, Dept Thorac Surg, Tokyo, Japan

[4] Hiratsuka Kyosai Hosp, Dept Pulm Med, Kanagawa, Japan

来源：

CHEMOTHERAPY | 2013年 / 59卷 / 01期

关键词：

Adjuvant chemotherapy; Carboplatin; Feasibility; Non-small cell lung cancer; NSCLC; S-1; Thrombocytopenia; VINORELBINE PLUS CISPLATIN; EXPRESSION LEVELS; PHASE-III; DIHYDROPYRIMIDINE DEHYDROGENASE; THYMIDYLATE SYNTHASE; GASTRIC-CANCER; STAGE-IB; TRIAL; PACLITAXEL; JAPAN;

D O I：

10.1159/000351101

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: The purpose of this study was to evaluate the feasibility and compliance of adjuvant chemotherapy of S-1 plus carboplatin for patients with completely resected non-small cell lung cancer (NSCLC) of pathological stage IB-IIIB. Methods: S-1 was given orally at a dose of 80 mg/m(2)/day for 2 weeks, followed by a 2-week period of no treatment. Carboplatin was given intravenously on day 8 at an area under the curve of 6. This regimen was repeated for four to six 28-day courses. Results: Seventeen patients were enrolled in this study. Fourteen of them completed at least 4 cycles of chemotherapy. Nine patients had grade 2 and three patients had grade 3 thrombocytopenia, respectively. Severe nonhematologic toxicities were uncommon. Treatment was delayed in a few patients because of prolonged thrombocytopenia. Conclusion: We concluded that the regimen was feasible and tolerable for patients with completely resected NSCLC as adjuvant chemotherapy. Copyright (c) 2013 S. Karger AG, Basel

引用

页码：35 / 41

页数：7

共 50 条

[21] Phase II Trial of Adjuvant Chemotherapy with Bi-Weekly Carboplatin Plus Paclitaxel in Patients with Completely Resected Non-small Cell Lung Cancer
Sugaya, Masakazu
Uramoto, Hidetaka
Uchiyama, Akihiko
Nagashima, Akira
Nakanishi, Ryoichi
Sakata, Hisanobu
Nakanishi, Kozo
Hanagiri, Takeshi
Yasumoto, Kosei
ANTICANCER RESEARCH, 2010, 30 (07) : 3039 - 3044
[22] A FEASIBILITY STUDY OF SPLIT-DOSE CISPLATIN AND VINORELBINE AS ADJUVANT CHEMOTHERAPY FOR COMPLETELY RESECTED NON-SMALL CELL LUNG CANCER
Hirai, Fumihiko
Toyozawa, Ryou
Inamasu, Eiko
Kojo, Miyako
Toyokawa, Gouji
Shiraishi, Yoshimasa
Morodomi, Yosuke
Takenaka, Tomoyoshi
Yamaguchi, Masafumi
Seto, Takashi
Takenoyama, Mitsuhiro
Ichinose, Yukito
JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S483 - S483
[23] Feasibility study of adjuvant chemotherapy with gemcitabine and split-dose cisplatin for completely resected non-small-cell lung cancer
Funai, Kazuhito
Takamochi, Kazuya
Itaya, Toru
Mochizuki, Takahiro
Nakamura, Toru
Toyoda, Futoru
Yong-Il, Kim
Sasaki, Kazuyoshi
Momiki, Shigeru
Takahashi, Tsuyoshi
Neyatani, Hiroshi
Suzuki, Kazuya
LUNG CANCER, 2010, 68 (01) : 78 - 83
[24] A Randomized Phase II Trial of Adjuvant Chemotherapy with Bi-weekly Carboplatin plus Paclitaxel versus Carboplatin plus Gemcitabine in Patients with Completely Resected Non-small Cell Lung Cancer
Uramoto, Hidetaka
Nakanishi, Ryoichi
Nagashima, Akira
Uchiyama, Akihiko
Inoue, Masaaki
Osaki, Toshihiro
Yoshimatsu, Takashi
Sakata, Hisanobu
Nakanishi, Kozo
Yasumoto, Kosei
ANTICANCER RESEARCH, 2010, 30 (11) : 4695 - 4699
[25] Carboplatin-Pemetrexed Adjuvant Chemotherapy in Resected Non-small Cell Lung Cancer (NSCLC): A Phase II Study
Karapanagiotou, Eleni M.
Boura, Paraskevi G.
Papamichalis, George
Konstantinou, Marios
Sepsas, Evangellos
Chamalakis, George
Simsiris, Panagiotis
Gkiozos, Ioannis
Syrigos, Kostas N.
ANTICANCER RESEARCH, 2009, 29 (10) : 4297 - 4301
[26] Adjuvant Chemotherapy is Effective for Completely Resected Stage IB Non-Small Cell Lung Cancer
Nakata, M.
Nojima, Y.
Nanba, K.
Saisho, S.
Shimizu, K.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S845 - S846
[27] A phase II randomized trial of adjuvant chemotherapy with S-1 versus S-1 plus cisplatin for completely resected pathological stage II/IIIA non-small cell lung cancer
Okarnoto, Tatsuro
Yano, Tokujiro
Shimokawa, Mototsugu
Takeo, Sadanori
Yamazaki, Koji
Sugio, Kenji
Takenoyama, Mitsuhiro
Nagashima, Akira
Tsukamoto, Shuichi
Hamatake, Motoharu
Yokoyama, Hideki
Ueda, Hitoshi
Motohiro, Akira
Tagawa, Tetsuzo A.
Shoj, Fumihiro
Kometanie, Takuro
Saito, Genkichi
Fukuyamap, Yasuro
Toyokawa, Gouji
Osoegawa, Atsushi
Emie, Yasunori
Maeharaa, Yoshihiko
LUNG CANCER, 2018, 124 : 255 - 259
[28] Adjuvant chemotherapy for completely resected non-small cell lung cancer: A systematic review
Alam, Naveed
Darling, Gail
Evans, William K.
Mackay, Jean A.
Shepherd, Frances A.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2006, 58 (02) : 146 - 155
[29] Survival After Adjuvant Chemotherapy in Completely Resected N1 Non-Small Cell Lung Cancer
Wang, E.
Bourdages-Pageau, E.
Gagnon, H.
Labbe, C.
Tremblay, L.
Ugalde, P.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S633 - S633
[30] Phase II study of nedaplatin and irinotecan as adjuvant chemotherapy for completely resected non-small cell lung cancer
Shuji Murakami
Haruhiro Saito
Tetsuro Kondo
Hiroyuki Ito
Fumihiro Oshita
Kouzo Yamada
Cancer Chemotherapy and Pharmacology, 2018, 81 : 81 - 87

← 1 2 3 4 5 →